Recent and archived news stories on: Biotechnology, Doctors, Drugs, Health Insurance, HMO's/PPO's, Hospitals, Medical Devices, Nursing...

Psychosis Drug Also Shows Promise in Dementia Cases

Nuplazid Nets $94.6 Million In Q3 SalesA drug from Acadia Pharmaceuticals made dementia patients nearly three times less likely to relapse into psychosis.

San Diego Companies Find Deals and Dollars at Health Conference

Two DNA sequencing companies raised more than $140 million combined, Daré Bioscience inked a potential commercialization deal worth up to $310 million, and Human Longevity sold its cancer division for $37 million, and separately, acquired a company.

Tease photo

Neurocrine Gains Option to License Epilepsy Drug; Deal Worth up to $412M

San Diego-based Neurocrine could buy the rights to yet another experimental epilepsy drug, per a recently announced agreement that could be worth up to $412 million.

DNA Sequencing Company Element Biosciences Raises $80.3M Round

Element Biosciences, another San Diego upstart that’s trying to make DNA technology more accessible, recently raised an $80.3 million round.

Tandem Diabetes Software Gets FDA OK

Closed-Loop System Controls Low and High Blood Sugar.

Tease photo

Epirium to Take on Muscle Diseases, Aging

BIOTECH: Company focused on mitochondria health, raises $85M round

Boosting ambitious plans, Epirium recently secured an $85 million Series A round, amid greater investment in muscle therapies.

Foundation Readies To Take On Ultra-Rare Diseases

Former Ionis CEO To Take Helm At Nonprofit.

Toolbox Medical Gets Cos. to Next Level

DEVICE: Product Development, CRO Services Focus on Diagnostics

Point-of-care diagnostic testing, which allows consumers and professionals to get quick lab-quality test results within minutes, has become a huge business.

Tease photo

Medical Device Cos. Applaud Tax Repeal

HEALTH: Excise Tax Was an ACA Financing Mechanism

A recently signed federal spending bill repealed a 2.3% excise tax on medical device makers that was scheduled to resume this month, a boon to San Diego’s medtech industry.

Tease photo

With $4M in Funding, n-Lorem Foundation to Take on Rare Genetic Diseases

After three decades helming Carlsbad’s Ionis Pharmaceuticals, Stanley Crooke stepped down at the end of 2019. Retirement isn’t for him, it seems.

PharmAkea to Merge with Galecto

San Diego’s PharmAkea is merging with Denmark-based Galecto, a deal the companies said would combine overlapping drug development programs aimed at cancer and fibrosis.

Regulatory Hurdle Too High for Illumina

TECH: Co. Scraps Planned $1.2 Billion PacBio Acquisition

San Diego’s Illumina will no longer buy Pacific Biosciences for $1.2 billion, a decision the companies mutually reached following antitrust action on both sides of the pond. Pacific Biosciences, or PacBio, had the potential to add another dimension to Illumina’s DNA-reading technology that’s the backbone of everything from ancestry tests to prenatal screening. But last month, the U.S. Federal Trade Commission moved to block the transaction, and the U.K.’s Competition and Markets Authority in October said it might do the same. $98M Breakup Fee Per a Jan. 2 announcement, Illumina will pay a $98 million break-up fee to PacBio. But PacBio must repay the money if it strikes an agreement to be acquired by Sept. 30 and consummates the deal within two years. Illumina climbed to the top of the DNA sequencing market with short-read sequencing that amplifies snippets of DNA. Pacific Biosciences, or Pac

Organovo and Tarveda to Merge

Deal To Give Tarveda Access to Nasdaq

San Diego-based Organovo last summer put itself up for sale, after its implantable liver program failed a clinical trial.

Tease photo

Illumina, Pacific Biosciences Call Off $1.2B Deal

San Diego’s Illumina will no longer buy Pacific Biosciences for $1.2 billion, a decision the companies reached following antitrust action on both sides of the pond.

Organovo and Tarveda Therapeutics Agree to Merge

Recently, publicly-traded Organovo and Tarveda Therapeutics agreed to merge. The deal will take privately-held Tarveda public.